Sugi Predict

Sugi Predict / Compounds / SCHEMBL2469559

SCHEMBL2469559

SCHEMBL2469559

O=C(COc1ccc(Cl)cc1)N1CCC(C(=O)NCCCc2ccccc2)(c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.55
▸ GPR183 P32249 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ ADAMTS5 Q9UNA0 3/20 0.52
▸ ADAMTS4 O75173 1/20 0.52
▸ CHRM5 P08912 1/20 0.52
▸ CHRM3 P20309 1/20 0.52
▸ POLB P06746 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ RCE1 Q9Y256 1/20 0.47
▸ PKM P14618 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ EPHX2 P34913 2/20 0.47
▸ HTT P42858 1/20 0.46
▸ GHSR Q92847 1/20 0.46
▸ ENPP2 Q13822 1/20 0.46
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13182941 0.93 CHRM5 (0.53) MEN1GPR183KMT2ACHRM5CHRM3
SCHEMBL2470378 0.89 CHRM5 (0.68) MEN1GPR183KMT2ACHRM5CHRM3
SCHEMBL2473451 0.88 MEN1 (0.59) MEN1GPR183KMT2AADAMTS5POLB
SCHEMBL2469030 0.88 MEN1 (0.49) MEN1GPR183KMT2ACHRM5CHRM3
SCHEMBL14312489 0.85 MEN1 (0.53) MEN1GPR183KMT2AADAMTS5ADAMTS4
SCHEMBL12195711 0.83 USP2 (0.49) MEN1GPR183KMT2ACHRM5CHRM3
SCHEMBL2468545 0.83 ALDH1A1 (0.66) MEN1GPR183KMT2ACHRM5CHRM3
SCHEMBL13183048 0.82 CHRM5 (0.59) MEN1KMT2ACHRM5CHRM3POLB
SCHEMBL2702458 0.81 KMT2A (0.62) MEN1GPR183KMT2APOLBMAPT
SCHEMBL2471715 0.81 ALDH1A1 (0.57) MEN1GPR183KMT2ACHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 — — EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 — — EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 — — US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 — — US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 — — US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885GPR183 3741/4885KMT2A 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.